GTBP - GT Biopharma Inc

GTBP - GT Biopharma Inc

https://www.gtbiopharma.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

GlobeNewswire • 1 month ago • score: 0.18

The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observedThe company plans on releasing initial Phase 1 results later in 2025 following completion of ...

GT Biopharma Appoints New Member to its Board of Directors

GlobeNewswire • 3 months ago • score: 0.38

SAN FRANCISCO, CALIFORNIA, June 13, 2025 ( GLOBE NEWSWIRE ) -- GT Biopharma, Inc. ( the "Company" ) ( NASDAQ: GTBP ) , a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer ( NK ) cell engager platform, ...

EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results - GT Biopharma ( NASDAQ:GTBP )

Benzinga • 3 months, 3 weeks ago • score: 0.12

GT Biopharma completed dosing in Cohort 1 and began Cohort 2 of its Phase 1 trial for GTB-3650 with no safety concerns. Early data shows increased NK cell activity, indicating promising immune response from its TriKE cancer therapy.

GT Biopharma Appoints New Member to its Board of Directors

GlobeNewswire • 4 months ago • score: 0.28

SAN FRANCISCO, CALIFORNIA, May 14, 2025 ( GLOBE NEWSWIRE ) -- GT Biopharma, Inc. ( the "Company" ) ( NASDAQ: GTBP ) , a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer ( NK ) cell engager platform, ...

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GlobeNewswire • 11 months, 2 weeks ago • score: 0.33

SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 ( GLOBE NEWSWIRE ) -- GT Biopharma, Inc. ( the "Company" ) ( NASDAQ: GTBP ) , a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer ( NK ) cell engager TriKE® platform, ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California.

52W High

$4.10

52W Low

$0.88

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.37

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.09

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.18

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

20.50%

Institutions (25–75% balanced)

15.16%

Shares Outstanding

3,557,500

Float

2,183,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-3.98

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.82%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.2883

Previous

-0.3011

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025